Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Cash (2019 - 2025)

Historic Change in Cash for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $168.5 million.

  • Nurix Therapeutics' Change in Cash rose 143859.22% to $168.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $137.0 million, marking a year-over-year increase of 14748.06%. This contributed to the annual value of $137.0 million for FY2025, which is 14748.06% up from last year.
  • As of Q4 2025, Nurix Therapeutics' Change in Cash stood at $168.5 million, which was up 143859.22% from -$5.8 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Change in Cash ranged from a high of $168.5 million in Q4 2025 and a low of -$66.9 million during Q4 2021
  • Its 5-year average for Change in Cash is $6.4 million, with a median of $2.5 million in 2022.
  • In the last 5 years, Nurix Therapeutics' Change in Cash tumbled by 268154.82% in 2023 and then skyrocketed by 143859.22% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Change in Cash (Quarter) stood at -$66.9 million in 2021, then surged by 125.28% to $16.9 million in 2022, then decreased by 27.16% to $12.3 million in 2023, then decreased by 11.12% to $11.0 million in 2024, then soared by 1438.59% to $168.5 million in 2025.
  • Its last three reported values are $168.5 million in Q4 2025, -$5.8 million for Q3 2025, and $8.3 million during Q2 2025.